Meredith Cook Sells 250 Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Stock

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) VP Meredith Cook sold 250 shares of the business’s stock in a transaction on Friday, April 12th. The shares were sold at an average price of $67.79, for a total transaction of $16,947.50. Following the completion of the sale, the vice president now directly owns 59,731 shares in the company, valued at approximately $4,049,164.49. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.

Meredith Cook also recently made the following trade(s):

• On Tuesday, February 13th, Meredith Cook sold 250 shares of ANI Pharmaceuticals stock. The shares were sold at an average price of $56.04, for a total transaction of $14,010.00.

ANI Pharmaceuticals Stock Down 1.1 %

Shares of NASDAQ ANIP opened at $65.56 on Wednesday. The firm’s 50-day simple moving average is $64.41 and its 200 day simple moving average is $58.47. The company has a market cap of $1.38 billion, a price-to-earnings ratio of 78.05 and a beta of 0.79. The company has a quick ratio of 2.81, a current ratio of 3.57 and a debt-to-equity ratio of 0.66. ANI Pharmaceuticals, Inc. has a 12-month low of $36.99 and a 12-month high of $70.81.

ANI Pharmaceuticals (NASDAQ:ANIP) last issued its quarterly earnings results on Thursday, February 29th. The specialty pharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.58 by $0.20. The business had revenue of $131.65 million for the quarter, compared to the consensus estimate of $123.02 million. ANI Pharmaceuticals had a net margin of 3.86% and a return on equity of 18.06%. On average, research analysts expect that ANI Pharmaceuticals, Inc. will post 3.55 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in ANIP. New York State Teachers Retirement System lifted its position in ANI Pharmaceuticals by 0.9% during the 3rd quarter. New York State Teachers Retirement System now owns 22,180 shares of the specialty pharmaceutical company’s stock valued at $1,288,000 after purchasing an additional 200 shares during the period. Teachers Retirement System of The State of Kentucky lifted its position in ANI Pharmaceuticals by 5.4% during the 2nd quarter. Teachers Retirement System of The State of Kentucky now owns 3,881 shares of the specialty pharmaceutical company’s stock valued at $209,000 after purchasing an additional 200 shares during the period. The Manufacturers Life Insurance Company lifted its position in ANI Pharmaceuticals by 4.3% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 5,435 shares of the specialty pharmaceutical company’s stock valued at $316,000 after purchasing an additional 225 shares during the period. China Universal Asset Management Co. Ltd. lifted its position in ANI Pharmaceuticals by 93.6% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 513 shares of the specialty pharmaceutical company’s stock valued at $30,000 after purchasing an additional 248 shares during the period. Finally, Point72 Asset Management L.P. lifted its position in ANI Pharmaceuticals by 60.0% during the 2nd quarter. Point72 Asset Management L.P. now owns 776 shares of the specialty pharmaceutical company’s stock valued at $42,000 after purchasing an additional 291 shares during the period. Institutional investors and hedge funds own 76.05% of the company’s stock.

Wall Street Analyst Weigh In

ANIP has been the topic of several recent analyst reports. HC Wainwright boosted their target price on shares of ANI Pharmaceuticals from $73.00 to $83.00 and gave the company a “buy” rating in a research note on Monday, March 4th. Guggenheim boosted their target price on shares of ANI Pharmaceuticals from $70.00 to $77.00 and gave the company a “buy” rating in a research note on Tuesday, March 5th. Truist Financial boosted their target price on shares of ANI Pharmaceuticals from $72.00 to $80.00 and gave the company a “buy” rating in a research note on Friday, March 1st. Finally, Capital One Financial initiated coverage on shares of ANI Pharmaceuticals in a research note on Friday, March 15th. They issued an “overweight” rating and a $80.00 target price on the stock. Five research analysts have rated the stock with a buy rating, According to MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $80.00.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.